Trial Profile

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Aug 2024 According to a GenScript Biotech Corp media release, based on the data from this study, Ciltacabtagene-autoleucel drug has received approval in the China by National Medical Products Administration (NMPA) for the treatment multiple myeloma.
23 May 2024 According to a Legend Biotech media release, data from this study will be presented at the 2024 European Hematology Association's (EHA) Hybrid Congress.
02 Nov 2023 According to a Legend Biotech media release, data from this study will be presented at the 65th American Society of Hematology Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com